|
| |
About Apo-TriAvir
Apotex Inc., the largest Canadian owned pharmaceutical company
researched, developed and manufactured Apo-TriAvir. Apo-TriAvir is a
combination of 300mg Zidovudine, 150mg Lamivudine and 200mg
Nevirapine and is indicated for the treatment of HIV infection. Each
individual component of the product was evaluated in bioequivalence
studies and shown to be bioequivalent to the original products. Apo-TriAvir
was evaluated and approved under the provisions of the CAMR by
Health Canada and fully conforms to all the regulations and health
requirements for marketing a drug in Canada’s healthcare system. The
product is manufactured in our fully GMP compliant facilities in
Toronto, Ontario. Following approval by Health Canada, Apo-TriAvir
received pre-qualification status by the World Health Organization
(WHO).
|
 |
|
